Contemporary management of treatment-related dermatologic toxicities in gynecologic cancers: a systematic review based on evidence from 2021 to 2025

TL;DR

This review summarizes recent evidence on skin side effects from gynecologic cancer treatments and highlights new strategies to manage them effectively.

Contribution

A systematic review of the latest evidence (2021–2025) on dermatologic toxicities in gynecologic cancer treatment and novel mitigation approaches.

Findings

Subclinical skin damage from drugs like paclitaxel is an early, often asymptomatic effect.

Radiotherapy-related skin issues and severe effects from novel targeted therapies are major concerns.

3D printed radiotherapy devices and multidisciplinary care models show promise in mitigating skin toxicities.

Abstract

Gynecologic cancers are commonly managed with chemotherapy, radiotherapy, and targeted therapies, which are effective but frequently associated with significant skin side effects. These dermatologic toxicities substantially reduce patients’ quality of life and treatment adherence, highlighting the need for a comprehensive synthesis of the latest evidence to address this clinical challenge.

This systematic review summarizes the most up-to-date evidence (as of 2025) regarding treatment-induced skin damage in patients with gynecologic cancers. It focuses on synthesizing data related to the clinical manifestations, subclinical changes, risk factors, and management strategies of these skin toxicities.

Key findings include three critical areas of focus: subclinical skin damage (early, mostly asymptomatic changes induced by medications such as paclitaxel), radiotherapy-related skin issues, and severe skin effects associated with novel targeted therapies. Additionally, innovative technologies (e.g., 3D printed radiotherapy devices) were identified as potential tools for preventing and mitigating dermatologic toxicities.

The review emphasizes the importance of individualized intervention plans and multidisciplinary care models to effectively manage treatment-related skin toxicities. By synthesizing the latest evidence on manifestations, mechanisms, risk factors, and innovative mitigation strategies, this review aims to provide clinicians with optimal information to improve outcomes for gynecologic cancer patients experiencing skin toxicities, thereby enhancing treatment adherence and overall patient well-being.